Alaunos Therapeutics Inc (TCRT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2010 | 09-2010 | 06-2010 | 03-2010 | 12-2009 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 60,392 | 66,471 | 73,662 | 45,044 | 48,839 |
| TOTAL | $60,816 | $66,823 | $73,941 | $45,356 | $49,193 |
| Non-Current Assets | |||||
| PPE Net | 253 | 230 | 216 | 196 | 255 |
| Other Non-Current Assets | 451 | 397 | 299 | 288 | 288 |
| TOTAL | $704 | $627 | $515 | $484 | $543 |
| Total Assets | $61,520 | $67,450 | $74,456 | $45,840 | $49,736 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,031 | 1,088 | 1,143 | 1,468 | 1,789 |
| Accrued Expenses | 2,538 | 2,978 | 1,139 | 1,322 | 1,261 |
| TOTAL | $3,612 | $4,106 | $2,305 | $2,833 | $3,095 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 43 | 40 | 23 | 43 | 45 |
| Other Non-Current Liabilities | 27,311 | 21,085 | 17,373 | 31,564 | 18,471 |
| TOTAL | $27,355 | $21,140 | $17,433 | $31,621 | $18,537 |
| Total Liabilities | $30,967 | $25,246 | $19,738 | $34,454 | $21,632 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 439 | 324 | 326 | 279 | 277 |
| Common Shares | 48 | 49 | 49 | 42 | 42 |
| Retained earnings | -123,814 | -111,963 | -99,758 | -108,797 | -91,144 |
| TOTAL | $30,553 | $42,204 | $54,718 | $11,386 | $28,104 |
| Total Liabilities And Equity | $61,520 | $67,450 | $74,456 | $45,840 | $49,736 |